Increased risk of developing peripheral neuropathy in patients coinfected with HIV-1 and HTLV-2

Journal of Acquired Immune Deficiency Syndromes

Volumn 31, Issue 4, 2002, Pages 440-447

  Zehender, Gianguglielmo ^a   Colasante, Chiara ^a   Santambrogio, Sara ^a   De Maddalena, Chiara ^a   Massetto, Benedetta ^a   Cavalli, Barbara ^a   Jacchetti, Gaia ^b   Fasan, Marco ^b   Adorni, Fulvio ^c   Osio, Maurizio ^a   Moroni, Mauro ^a   Galli, Massimo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c CNR   (Italy)

Author keywords

AIDS progression; HTLV 2 HIV 1 coinfection; Myelopathy; Peripheral neuropathy; TSP HAM

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EFFECT; FOLLOW UP; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN T CELL LEUKEMIA VIRUS 2; HUMAN T CELL LEUKEMIA VIRUS INFECTION; HYPOTHESIS; LYMPHOCYTE COUNT; MORTALITY; OBSERVATION; OPPORTUNISTIC INFECTION; PATHOGENESIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RISK FACTOR; SPINAL CORD DISEASE;

EID: 0036892036     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200212010-00011     Document Type: Article

References (40)

1. Gessain A, de The G. What is the situation of human T cell lymphotropic virus type II (HTLV-II) in Africa? Origin and dissemination of genomic subtypes. J Acquir Immune Defic Syndr Hum Retrovirol 1996;13:S228-35.
2. Hall WW, Ishak R, Zhu SW, et al. Human T lymphotropic virus type II (HTLV-II): Epidemiology, molecular properties, and clinical features of infection. J Acquir Immune Defic Syndr Hum Retrovirol 1996;13:S204-14.
3. Zanetti AR, Zehender G, Tanzi E, et al. HTLV-II among Italian intravenous drug users and hemophiliacs. Eur J Epidemiol 1992; 8:702-7.
4. Soriano V, Gutierrez M, Merino F, et al. Recent spread of human T lymphotropic virus type II among injecting drug users in Spain. HTLV Spanish Study Group. J Infect Dis 1996;174:891-3.
5. Murphy EL, Fridey J, Smith JW, et al. HTLV-associated myelopathy in a cohort of HTLV-I and HTLV-II-infected blood donors. The REDS Investigators. Neurology 1997;48:315-20.
6. Lehky TJ, Flerlage N, Katz D, et al. Human T-cell lymphotropic virus type II-associated myelopathy: Clinical and immunologic profiles. Ann Neurol 1996;40:714-23.
7. Berger JR, Svenningsson A, Raffanti S, et al. Tropical spastic paraparesis-like illness occurring in a patient dually infected with HIV-1 and HTLV-II. Neurology 1991;41:85-7.
8. Berger JR. Myelopathy and coinfection with HIV and HTLV-I. Neurology 1997;49:1190-1.
9. Rosenblatt JD, Tomkins P, Rosenthal M, et al. Progressive spastic myelopathy in a patient co-infected with HIV-1 and HTLV-II: Autoantibodies to the human homologue of rig in blood and cerebrospinal fluid. AIDS 1992;6:1151-8.
10. Rosenblum MK, Brew BJ, Hahn B, et al. Human T-lymphotropic virus type I-associated myelopathy in patients with the acquired immunodeficiency syndrome. Hum Pathol 1992;23:513-9.
11. Zehender G, De Maddalena C, Osio M, et al. High prevalence of human T cell lymphotropic virus type II infection in patients affected by human immunodeficiency virus type 1-associated predominantly sensory polyneuropathy. J Infect Dis 1995;172: 1595-8.
12. Dooneief G, Marlink R, Bell K, et al. Neurologic consequences of HTLV-II infection in injection-drug users. Neurology 1996;46: 1556-60.
13. Beilke MA, Greenspan DL, Impey A, et al. Laboratory study of HIV-1 and HTLV-I/II coinfection. J Med Virol 1994;44:132-43.
14. Kalyanaraman VS, Sarngadharan MG, Robert-Guroff M, et al. A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia. Science 1982;218: 571-3.
15. Fouchard N, Flageul B, Bagot M, et al. Lack of evidence of HTLV-I/Il infection in T CD8 malignant or reactive lymphoproliferative disorders in France: A serological and/or molecular study of 169 cases. Leukemia 1995;9:2087-92.
16. Hjelle B, Mills R, Swenson S, et al. Incidence of hairy cell leukemia, mycosis fungoides, and chronic lymphocytic leukemia in first known HTLV-II-endemic population. J Infect Dis 1991;163: 435-40.
17. Zucker-Franklin D, Hooper WC, Evatt BL. Human lymphotropic retroviruses associated with mycosis fungoides: Evidence that human T-cell lymphotropic virus type II (HTLV-II) as well as HTLV-I may play a role in the disease. Blood 1992;80:1537-45.
18. Poiesz B, Dube D, Dube S, et al. HTLV-II-associated cutaneous T-cell lymphoma in a patient with HIV-1 infection. N Engl J Med 2000;342:930-6.
19. Page JB, Lai SH, Chitwood DD, et al. HTLV-I/II seropositivity and death from AIDS among HIV-1 seropositive intravenous drug users. Lancet 1990;335:1439-41.
20. Visconti A, Visconti L, Bellocco R, et al. HTLV-II/HIV-1 coinfection and risk for progression to AIDS among intravenous drug users. J Acquir Immune Defic Syndr Hum Retrovirol 1993;6: 1228-37.
21. Bartholomew C, Blattner W, Cleghorn F. Progression to AIDS in homosexual men co-infected with HIV and HTLV-I in Trinidad. Lancet 1987;2:1469.
22. Hattori T, Koito A, Takatsuki K, et al. Frequent infection with human T-cell lymphotropic virus type I in patients with AIDS but not in carriers of human immunodeficiency virus type. J Acquir Immune Defic Syndr Hum Retrovirol 1989;2:272-6.
23. Hershow RC, Galai N, Fukuda K, et al. An international collaborative study of the effects of coinfection with human T-lymphotropic virus type II on human immunodeficiency virus type I disease progression in injection drug users. J Infect Dis 1996; 174:309-17.
24. Anonymous. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992;41:1-19.
25. Simpson DM, Tagliati M. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995;9:153-61.
26. Anonymous. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force. Neurology 1991;41: 778-85.
27. Anonymous. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Neurology 1991;41:617-8.
28. Anonymous. AIDS: Proposed WHO criteria for interpreting western blot assays for HIV-1, HIV-2, and HTLV-I/HTLV-II. Bull World Health Organ 1991;69:127-9, 131-3.
29. Zehender G, De Maddalena C, Gianotto M, et al. High prevalence of false-negative anti-HTLV type I/II enzyme-linked immunosorbent assay results in HIV type 1-positive patients. AIDS Res Hum Retroviruses 1997;13:1141-6.
30. Zehender G, Meroni L, Varchetta S, et al. Human T-lymphotropic virus type 2 (HTLV-2) provirus in circulating cells of the monocyte/macrophage lineage in patients dually infected with human immunodeficiency virus type 1 and HTLV-2 and having predominantly sensory polyneuropathy. J Virol 1998;72:7664-8.
31. Magnani G, Elia G, Casoli C, et al. HTLV-II does not adversely affect the natural history of HIV-1 infection in intravenous drug users. Infection 1995;23:63.
32. Berger AR, Schaumburg HH, Gourevitch MN, et al. Prevalence of peripheral neuropathy in injection drug users. Neurology 1999;53: 592-7.
33. Wulff EA, Simpson DM. Neuromuscular complications of the human immunodeficiency virus type 1 infection. Semin Neurol 1999; 19:157-64.
34. Barohn RJ, Gronseth GS, LeForce BR, et al. Peripheral nervous system involvement in a large cohort of human immunodeficiency virus-infected individuals. Arch Neurol 1993;50:167-71.
35. Tagliati M, Grinnell J, Godbold J, et al. Peripheral nerve function in HIV infection: Clinical, electrophysiologic, and laboratory findings. Arch Neurol 1999;56:84-9.
36. Araujo AQ, Andrade-Filho AS, Castro-Costa CM, et al. HTLV-I-associated myelopathy/tropical spastic paraparesis in Brazil: A nationwide survey. HAM/TSP Brazilian Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 1998;19:536-41.
37. Maloney EM, Cleghorn FR, Morgan OS, et al. Incidence of HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Jamaica and Trinidad. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:167-70.
38. Sadler M, Nelson M. Peripheral neuropathy in HIV. Int J STD AIDS 1997;8:16-21.
39. Murphy EL, Glynn SA, Fridey J, et al. Increased incidence of infectious diseases during prospective follow-up of human T-lymphotropic virus type II- and type I-infected blood donors. Arch Intern Med 1999;159:1485-91.
40. Jacobson S, Lehky T, Nishimura M, et al. Isolation of HTLV-II from a patient with chronic, progressive neurologic disease clinically indistinguishable from HTLV-I-associated myelopathy/tropical spastic paraparesis. Ann Neurol 1993;33:392-6.